Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04771572 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia, sponsored by Newave Pharmaceutical.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT04771572 is a Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia that is actively recruiting participants, run by Newave Pharmaceutical. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT04771572, a Phase 1 study of Multiple Myeloma and Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Newave Pharmaceutical.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Conditions Studied
Interventions
- DRUG LP-118
Study Locations (8)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- University of Cincinnati - Cincinnati
- The Ohio State University - Columbus
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
North Carolina
- University of North Carolina - Chapel Hill
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04771572
The ClinicalTrials.gov registry entry for NCT04771572 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The listed sponsor is Newave Pharmaceutical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which LP-118 is the first listed.
NCT04771572 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Ohio, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04771572 about?
NCT04771572 is a clinical study titled "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.". This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
What is the current status of trial NCT04771572?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2021-08-23. Estimated completion is 2025-10-01.
What conditions does trial NCT04771572 study?
This clinical trial studies the following conditions: Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Myelofibrosis.
What interventions are being tested in trial NCT04771572?
The interventions under investigation include: LP-118 (DRUG).
Who is sponsoring clinical trial NCT04771572?
This trial is sponsored by Newave Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04771572 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.